Circassia Puts Aside R&D, Aims To Grow Commercial Platform
Executive Summary
UK biotech Circassia puts Phase III cat allergy vaccine failure behind it and intends to move forward with building its commercial platform, and sales, in the respiratory sector.
You may also be interested in...
Bouncing Back From A Phase III Flop
The passing of a decade always brings with it an inevitable glance in the rear-view mirror to see how far we have come. The pharma industry is no different and it would be remiss to ignore the failings of the industry’s collective R&D engine while also celebrating its successes.
Circassia Ends AZ Deal To Dig Itself Out Of Debt Hole
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
Autolus Faces Life After Woodford With New Czech Backer
PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.